Arthur Hayes, co-founder of BitMEX, warns that upcoming IPOs by major AI companies like SpaceX, Anthropic, and OpenAI could cause significant share dilution and lower tech stock valuations. This dilution may reduce banks' willingness to lend, shrinking dollar liquidity and pressuring Bitcoin and other risk assets. However, Hayes suggests that if this leads to a financial crisis, central banks might respond with monetary easing, potentially boosting Bitcoin in the longer term.
Arthur Hayes' warning on AI IPOs and their potential impact on liquidity and Bitcoin comes as a backdrop to current crypto market trends. For readers following cryptocurrency, here is Pluang's market snapshot as of Nov 05, 2026 16:21 WIB: out of 50 major cryptocurrencies, 41 rose and 8 fell today. Ethereum (ETH) traded at Rp43.806.964 with a 1-day change of +3.89%, Litecoin (LTC) at Rp1.023.567 with +3.83%, and Solana (SOL) at Rp1.752.730 with +3.75%.
Wolters Kluwer repurchased 499 of its ordinary shares between October 29 and November 4, 2026, spending €0.04 million at an average price of €85.06 per share. This is part of a larger 2026 share buyback program aiming to repurchase shares worth up to...
Lorenz Snacks has introduced a fleet of four autonomous, electric vehicles from Einride at its production site in Neunburg vorm Wald, Germany. These vehicles will handle in-plant transport of goods and materials, replacing diesel trucks and significa...
Futu Holdings Limited will announce its financial results for the third quarter ending September 30, 2026, on November 19 before U.S. market open. The company will host a live earnings conference call at 7:30 AM ET (8:30 PM Beijing/Hong Kong time) th...
UBS Group AG notified Bang & Olufsen A/S that its shareholding and voting rights exceeded 5% as of October 30, 2026, but fell below 5% by November 2, 2026. As of November 2, UBS held 4.66% of Bang & Olufsen's total shares and voting rights. This chan...
T-Therapeutics secured $133 million in an oversubscribed Series B funding round led by Advent Life Sciences and British Business Bank to develop its first-in-class TCR-CD3 bispecific therapies targeting cancer and autoimmune diseases. The funds will ...
